A total of 50 consecutive patients (median age, 57.5 years) with AML (n ¼ 30) or myelodysplasia (MDS, n ¼ 20) underwent HLA matched related donor (MRD, n ¼ 27) or unrelated donor (MUD, n ¼ 23) peripheral blood hematopoietic cell transplantation after nonmyeloablative CY/fludarabine (Flu) conditioning. GVHD prophylaxis included CsA (n ¼ 19) ± mycophenolate mofetil (n ¼ 31). At a median follow-up of 59 months, 21 patients (42%) were alive without evidence of disease. By Kaplan-Meier analysis, year 1-4 disease-free survival (DFS) and OS estimates were 0.50/0.58, 0.40/0.46, 0.37/0.43 and 0.37/0.41. MUD recipients were engrafted quickly (13.5 days) compared to MRD recipients (16 days) and relapsed/progressed less frequently (P ¼ 0.005). Overall grade 3/4 acute GVHD (aGVHD) occurred in 26% in the absence of antecedent mucositis and was associated with chronic GVHD (cGVHD) and poor OS. Extensive cGVHD developed in 51.2% of 100 day survivors. Rates of aGVHD, cGVHD and survival were similar between MRD and MUD recipients. Of 14 survivors with cGVHD, 5 (35.7%) experienced resolution off immunosuppression, suggesting that tolerance with HLA matched grafts is possible at an advanced age by this method. This study provides further evidence for prolonged DFS after CY/Flu MRD allotransplantation for AML/MDS, and extends the findings to older patients and those with unrelated donors.
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Myeloablative conditioning regimens have traditionally been used for treatment; however, recognition of alloimmune anticancer effects has redirected clinical HCT efforts toward methods that use less toxic conditioning for patients with HLA matched donors. [6] [7] [8] Phase I trials using reducedintensity conditioning (RIC) followed by allogeneic HCT suggest that older patients with hematological malignancies experience decreased early TRM and morbidity, evidence for antitumor effects and variable rates of donor engraftment and GVHD. [9] [10] [11] [12] [13] Early reports of RIC in AML/MDS showed high rates of engraftment and low TRM; results of studies with lengthy follow-up are mixed regarding the durability of disease responses. [14] [15] [16] [17] [18] It is also not known to what extent a state of tolerance and immunological reconstitution is possible in older patients. [19] [20] [21] These questions are important, given that TRM and morbidity are significantly reduced when less intense conditioning is administered to older patients in whom these disorders are prevalent. 22, 23 Although reduced-intensity regimens are associated with decreased toxicity to recipient tissues compared with highdose 'conventional' conditioning, most RIC regimens are sufficiently intense to ablate recipient marrow function, and cells obtained from the recipient in the early post transplant period are usually completely donor derived (full chimerism). Khouri et al. 7 Childs et al. 9 and Storb et al. 12 initially showed that the purine analogue, fludarabine (Flu), given with the alkylating agent CY or low-dose TBI permits engraftment without myeloablation. Such regimens are associated with very low toxicity rates (that is, mucositis, hepatic injury), are characterized by an initial period of mixed chimeric lymphohematopoietic engraftment and permit autologous marrow recovery in the event of primary allograft failure. 9, 12, 13, 24, 25 These particular regimens may be designated as 'minimally intense' or 'nonmyeloablative'. 23, [26] [27] [28] The Indiana University (IU) Stem Cell Transplantation Program adopted a CY/Flu regimen as a nonmyeloablative approach for treatment of hematological malignancies in older patients or those whose risk for complications of myeloablative transplantation seemed too high. 9 The purpose of this study was to assess engraftment rates, toxicities and outcomes of patients transplanted for AML/MDS.
Patients, donors and methods
Institutional review board-approved companion nonmyeloablative protocols were designed and implemented at the IU Cancer Center in May 2000, using the Childs et al. conditioning regimen for patients with a matched related (MRD) or unrelated (MUD) donor. Inclusion criteria considered the hematological malignancy, stage of disease and subject age, and included the following: (1) high-risk MDS or AML, (2) relapsed advanced hematological malignancies after autograft or (3) refractory disease. The following patients were considered eligible: (1) age over 50 with an indication for allogeneic transplantation or (2) a comorbid condition or poor Eastern Cooperative Oncology Group (ECOG) Study performance status. Patient preference for lower-intensity conditioning was considered in selected cases following comprehensive counseling regarding the differences between nonmyeloablative and myeloablative SCT. Exclusion criteria included the following: (1) active central nervous system disease, (2) pregnancy, (3) SGOT more than three times the upper limit of normal, (4) creatinine clearance o50 ml/h or glomerular filtration rate o50 ml/min per 1.73/m 2 , (5) earlier allogeneic transplant, (6) abnormal fractional shortening by echocardiogram and (7) lung diffusion capacity of o50% of predicted normal, corrected for anemia.
Donors were required to be HIV seronegative, hepatitis B antigen-negative and HLA 6/6 or 5/6 MRD (HLA-A, HLA-B and HLA-DR loci; serological class I, highresolution class II) or 6/6 matched unrelated. 29 A total of 49 patients underwent treatment with G-CSF followed by apheresis that started on the fifth day as described. 30 Apheresis was performed on 1 additional day with the goal of obtaining 5 Â 10 6 CD34 þ cells per kg recipient body weight. One related donor could not undergo G-CSF mobilization and provided BM harvested under general anesthesia as per standard procedure.
Patients were admitted to a dedicated BMT unit with laminar airflow or HEPA-filtered rooms under conditions of reverse isolation. Acyclovir, fluconazole and quinolone were given to recipients for prophylaxis against viral, fungal and Gram-negative bacteria. CMV prophylaxis consisted of acyclovir followed by peripheral blood monitoring beginning day þ 7 until day þ 100. At day þ 100, monitoring was scheduled every 2 weeks until day þ 180. Patients with GVHD on active systemic immunosuppression that included glucocorticosteroids and/or monoclonal antibodies were monitored weekly. Initial monitoring was by rapid peripheral blood culture. Later, we incorporated quantitative PCR, an assay with a lower limit of detection of 100 copies per ml (Viracor, Lee's Summit, MO, USA). 31 CY, 60 mg/kg, was administered i.v. on days -6 and À7 (total dose 120 mg/kg). Uroprotection consisted of forced diuresis and sodium 2-mercaptoethane-sulfonate (Mesna). Fludarabine, 25 mg/m 2 , was given i.v. as a single daily infusion for 5 consecutive days (days À5 to À1; total dose, 125 mg/m 2 ). Dosages of chemotherapy were adjusted for obese patients (4120% ideal body weight) by using the following formula: dosing weight ¼ ideal body weight þ (actualÀideal weight)/2.
Patients 1-19 received CsA (3 mg/kg, adjusted for weight/24 h) every 12 h beginning day -1. Dose was adjusted according to fasting levels to achieve therapeutic but nontoxic levels of 150-250 mg per 100 ml. Patients 20-50 received CsA and mycophenolate mofetil (MMF); 1000 mg b.i.d. i.v. or p.o. beginning day þ 1. Oral CsA was administered through day þ 100; in the absence of GVHD, it was tapered until discontinuation by approximately day þ 180. MMF was administered through day þ 60 and discontinued if there was no GVHD. Although several patients required CsA/MMF adjustments outside these parameters, the majority received CsA for at least 100 days and for those who received, MMF, at least 45 days. Patients with no GVHD, an ANC 4500 per mm 3 and peripheral blood chimerism 45% donor after day þ 30, or those with evidence for disease progression, were eligible to have immunosuppression reduced or discontinued. Patients who met the following criteria were eligible for a donor lymphocyte infusion (DLI) of 1 Â 10 6 CD3 þ cells per kg (1 Â 10 5 for MUD) recipient body weight, to be given after day þ 45: (1) no GVHD, (2) ANC 4500 per mm 3 and peripheral blood chimerism 45% donor and (3) evidence of disease progression. If GVHD of any grade developed between days þ 30 and þ 45, the patient was not eligible for donor lymphocyte infusion.
Unfractionated whole PBMC chimerism assessment was performed on DNA isolated from 2-3 ml whole blood (Gentra Kit Method; Gentra Systems, Minneapolis, MN, USA) analyzed by DNA RFLP or STR at the following time points: days þ 30, þ 60, þ 100, 6 months, 1 year and as clinically indicated. 32, 33 Evidence of donor engraftment was defined as an ANC 4500 per mm 3 at day þ 30 and 45% donor chimerism. Time to resolution of cytopenias was defined as the number of days post transplant required to reach an ANC 4500 per mm 3 for 3 consecutive days and platelet transfusion independence for 7 days followed by platelet count 420 000 per mm 3 for 3 consecutive days. The National Cancer Institute Common Toxicity Criteria version 2.0 was used for the evaluation of regimen-related toxicity and GVHD was evaluated by established severity scales. 34, 35 Cytogenetic risk factors were applied according to Greenberg et al. 36 and Slovak et al.
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The National Marrow Donor Program (NMDP) guidelines for classification of causes of death were used (form 190). Acute GVHD (aGVHD) was listed for patients who had severe, progressive aGVHD. If the patient had no aGVHD symptoms and died of an opportunistic infection while receiving immunosuppression, the infection was considered primary and aGVHD a contributing cause of death. We considered chronic GVHD (cGVHD) as the primary cause of death for patients with severe, symptomatic cGVHD. Infection or other complications were considered in these cases as a contributing cause of death. cGVHD was considered a contributing cause of death if the patient died of an opportunistic infection with controlled cGVHD while receiving immunosuppression. Infections that were indwelling venous catheter related were considered primary causes of death.
The initial study of patients with a variety of hematological malignancies finished accrual in October 2004 and outcomes were analyzed. Given the favorable results, the method was adopted at IU as a treatment plan for transplant candidates deemed not eligible for conventional conditioning. 
Statistical analyses
Baseline patient characteristics and survival information were compared between MRD and MUD groups and between those who received CsA and CsA/MMF. Fisher's exact test was used for categorical variables to account for small sample sizes; the t-test was used for continuous variables. In some cases, when the normality assumption was in question, the nonparametric Wilcoxon's signed-rank test was used for comparing two groups. The log-rank test was used for survival outcomes. When constructing the Kaplan-Meier curve for survival, patients alive at the end of the study were regarded as censored.
Results

Patients and donors
Thirty-one men (62%) and 19 women (38%) underwent nonmyeloablative allogeneic transplantation (NMAT) for AML/ MDS from May 2000 to 10 January 2008. The median age was 57.5 years (range, 17-66; median age of the recipients of MUD grafts was 57 vs 58 years for MRD recipients). Among them, 80% were more than 50 years. Of 50, 46 (92%) recipients and 19 (38%) of donors were CMV positive before transplant.
Fifty-six percent of recipients were not in remission at the time of transplant. Among them, 22 (44.0%) had AML in first (n ¼ 13) or second (n ¼ 9) CR; 2 were cytopenic after induction chemotherapy without increased marrow blasts; 2 had CMML that transformed to AML successfully induced to baseline CMML (coded as AML per NMDP guidelines); 1 had secondary AML and concomitant CLL; 
Multivariate analysis for time to ANC 4500 per mm 3 for MRD/MUD, including CD34 and CD3 cell dosages and GVHD prophylaxis (CsA vs CsA/MMF) rendered a P-value of 0.059. An ANC 42000 per mm 3 was reached at a median time of 18 days (range, 14-71 days), 18 and 19 days for MRD and MUD recipients, respectively (univariate P ¼ 0.363).
GVHD
Grades 2-4 and 3-4 aGVHD occurred in 38.0 and 26.0% of patients at a median of 27 and 21 days after MRD and MUD infusion, respectively. 'Late onset' aGVHD' was diagnosed in 1 patient and 11 (22.0%) fit the definition of 'serious GVHD' given by Flowers et al. 21, 38 There was no difference in rates of any (P ¼ 0.15) or grade 3-4 (P ¼ 0.48) aGVHD in patients who received CsA or CsA/MMF. cGVHD or extensive cGVHD occurred after a median of 184 days in 29 of 41 (70.7%) and 21 of 41 (51.2%) of 100-day survivors, respectively. The incidence of cGVHD was not different between MRD and MUD recipients (P ¼ 0.305). At a median of 4.7 years, 8 of 21 (38.1%) survivors were living with no GVHD, 3 (14.3%) had limited and 10 (47.6%) had extensive cGVHD, and ECOG performance status scores of 0 (n ¼ 18), 1 (n ¼ 2) and 2 (n ¼ 1). Two survivors required pulmonary specialty care for symptomatic bronchiolitis obliterans and no one experienced malabsorption or chronic liver disease. 39 
Transplant-related complications and survival
No patient experienced mucositis, lymphoproliferative disease or sinusoidal obstructive syndrome (SOS). Thrombotic microangiopathy with hemolytic anemia occurred in two patients; one contributed to a patient's death and one was resolved with discontinuation of CsA. 40 Nonhematological grade 4 toxicities included clinical/radiological findings consistent with obliterative bronchiolitis (n ¼ 3), all of whom had cGVHD. Of 50, 46 (92%) recipients and 19 (38%) donors were CMV positive before transplant.
Both donor and recipient were CMV seronegative in three (6%) transplants. During the initial year (or until death if survival o1 year) 62 (12.2%) of 759 post transplant direct tests (shell culture early antigen detection or PCR) were positive. Seventeen (34%) patients experienced CMV activation beginning a median of 59 days post transplant and it was resolved in 16 (94%) at a median of 90 days post transplant. One patient had CMV enteritis in the context of aGVHD as a cause of death; one patient had CMV esophagitis, also with GVHD that responded to treatment. Eleven skin cancers were diagnosed in six patients; all were excised without dissemination. in the DFS or OS rate between those with or without active disease (0.661). This may be explained by the high percentage of patients with high-risk cytogenetics in both groups and low number of patients in frank relapse at the time of transplant. Causes of death were disease relapse/progression (n ¼ 13), infection (n ¼ 6), GVHD (n ¼ 6) and other (n ¼ 4). MRD and MUD recipients were more likely to die from disease relapse and GVHD, respectively. Eight (16.0%) died during the first 100 days (two within 30 days), six of transplant-related causes and two of disease progression. OS in the AML group was 40% and in the MDS group it was 45% (P ¼ 0.726). Twenty-one surviving patients were in remission a median of 4.7 years post transplantation with ECOG performance status scores of 0 (n ¼ 18), 1 (n ¼ 2) and 2 (n ¼ 1).
Disease responses
Of 28, 26 patients with active disease at the time of transplant were evaluable for disease responses and 19 (73.1%) experienced a complete response, 5 (19.2%) a partial response, 1 each had stable disease and disease progression as the best response. Of 22 patients transplanted in remission, 14 of 20 evaluable maintained a CR (70%). A total of 15 of 50 (30.0%) patients relapsed/ progressed (MRD, 13; MUD, 2; P ¼ 0.005). The rate of disease progression or relapse was 70% in those who failed to achieve 100% donor chimerism by day þ 100; 86% of relapses/progressions occurred within the first year. Two of eight (25%) patients who relapsed reestablished lasting remissions with immunosuppressive withdrawal and DLI, respectively; there have been no relapses after 2 years of transplantation.
Discussion
Grigg et al. 42 recently reported results of a clinical investigation using nonmyeloablative CY/Flu to prepare 34 patients with de novo AML in first CR for matchedsibling allotransplantation. Patients experienced relatively low incidences of grades 2-4 aGVHD (21%) and cGVHD (24%). Thirteen (38%) patients relapsed and estimated DFS and OS at 2 years were 56 and 68%, respectively. 42 The current investigation extends these findings, with longer follow-up, to patients of advancing age and recipients of unrelated grafts, 75% of whom were not in first CR at the time of transplantation. Mucositis and SOS were avoided, predominantly donor chimerism occurred in all patients and DLI was not needed to encourage donor engraftment. Full donor chimerism was achieved by 6 months in most patients, which appears more rapid compared to the radiation-based nonmyeloablative method, in which mixed donor/recipient T cell chimeras remained in more patients 6 months post transplant. 27 Recipients of MUD allografts experienced low rates of disease progression and statistically equivalent rates of aGVHD, cGVHD and survival compared with MRD recipients. CY/Flu appears to suppress recipient resistance sufficiently to permit donor cells to deliver the antihematopoiesis activity required for engraftment. The rapid achievement of an ANC 4500 per mm 3 observed in MUD recipients is presumably due to the action of donor lymphocytes of greater histocompatibility disparity in an environment devoid of the highly potent immunosuppressives such as antithymocyte globulin or alemtuzumab. 43, 44 In this regard, the time to aGVHD was 21 days for MUD recipients compared to 27 days for MRD recipients.
CY and Flu are active pharmacological agents against myeloid neoplasms; therefore, observed disease responses cannot be unequivocally attributed to the allograft. 45 Nonetheless, it is important to realize that 39 (78%) of the entire cohort had either disease past first remission, poor risk cytogenetics (AML), secondary AML, RAEB, CMML or 'int-2'-'high' MDS as per IPSS. This is a patient population that would not be expected to be successfully treated with chemotherapy alone. The fact that a significant fraction of patients experienced durable remissions (some of whom whose cGVHD resolved) argues in favor of GVL effects active in the early post transplant period; this interpretation agrees with Kumar et al., who suggest that slow lymphocyte recovery after matched-sibling allogeneic BMT for AML predicts subsequent relapse. [46] [47] [48] [49] [50] In fact, the overall relapse rate of 30.0% at 4.7 years is comparable to that observed with RIC regimens or conventional allotransplantation. 1, [51] [52] [53] The particularly low relapse rate with MUD transplants (9%) suggests that given sufficient immunosuppression to effect engraftment, the risk of progression/relapse after MUD transplantation may be more fundamentally susceptible to increases in GVHD preventive intensity than the relative strength of conditioning. 18 The results that we have observed in patients with AML/MDS, many of whom had received chemotherapy as part of disease management before transplant, cannot be necessarily extrapolated to patients treated for other hematological malignancies; this pertains particularly to CML, as shown by Sloand et al.
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Results of reduced-intensity or minimal intensity, nonmyeloablative, AML/MDS disease-specific investigations with 2 and at least 3 years of follow-up that preceded this report are summarized in Tables 2 and 3 . There is one published minimally intensive allotransplant study in AML/MDS with 2 years median follow-up, and one other with at least 3 years of follow-up suitable for comparison. Scott et al.
16 treated 38 patients (median age, 62 years) with truly nonmyeloablative TBI or TBI/Flu and CsA/MMF GVHD prophylaxis (n ¼ 36), and compared results with a 112-patient cohort who received myeloablative BU/CY over the same period. In their study, 3-year OS was 27%, progression-free survival, 28% and nonrelapse mortality, 41%, findings that did not differ significantly between conventional and nonmyeloablative groups. 16 Hegenbart et al. reported findings of 122 patients treated at multiple centers using the same regimen with median follow-up of 44 months. Cumulative mortalities from disease progression were 47 and 33% at 2 years for MRD and MUD recipients, respectively. Overall 2-year survival was 48% and DFS, 44%. 58 The utility of mixed chimerism in limiting GVHD reported in animal models was not realized in this study. 25, 61, 62 A transient period of mixed chimerism was followed by the achievement of full donor chimerism relatively soon compared with a radiation-based minimally intensive nonmyeloablative regimen. 27 Clinically detectable mucositis was avoided and engraftment was initially characterized as mixed; nonetheless, the incidence of grade 3-4 aGVHD was similar to that observed after conventional conditioning and associated with the development of extensive cGVHD and poor survival in multivariate analysis. This finding provides evidence that injury to host tissues is not a requirement for aGVHD with this method; rather, the GVH reaction is likely activated by direct or indirect antigen presentation to donor lymphocytes through specific receptors propagated by selectively active cytokines. [63] [64] [65] [66] [67] [68] The onset appeared 1-2 weeks later than that usually observed after standard conditioning/prophylaxis and MMF appeared to add little, if any, anti-GVHD activity to CsA alone in this context, as predicted by Mohty et al. 69 Thirty percent of patients experienced no cGVHD, 47% with cGVHD have tolerated reductions in immunosuppression and 33% with extensive cGVHD have experienced resolution and are receiving no GVH therapy. Given the mean current survivor age of 63 years, tolerance induction appears possible in older patients conditioned in this manner without disease recurrence over extended periods.
We are currently studying the potential for eliminating in vivo alloreactive T cells, a form of negative selection in the post transplant period, with an inhibitor of activated T cells that is approved for solid organ rejection prevention, for a number of reasons. [70] [71] [72] First, over the years in the HLA matched setting, the addition of broadly active immunosuppressants or lymphocyte depletion has yet to limit the GVHD problem compared with standard calcineurininhibitor/MTX prophylaxis, without the consequence of higher relapse/progression rates. Second, patients referred to our institution for NMAT were of advanced age or with comorbid conditions and intermediate to poor cytogenetics, but not in florid relapse; therefore, a potent, welltolerated therapy for older recipients with high-risk features and low tumor burden is needed. Third, we saw no apparent additional anti-GVHD prophylactic activity with adjunctive MMF. 69, 73 Finally, the rapid engraftment dynamic, relatively early achievement of full donor chimerism and potent GVL effects presumably delivered soon after transplant, appears to support such a concept. 44 A minimal intensity HCT allotransplant approach might then be considered an attractive therapeutic option for those of advancing age with AML/MDS and either an HLA MRD or MUD.
